Industry
A Better Way to Track Representative Payee Services
For health organizations providing representative payee services, tracking expenses can be time-consuming, particularly when managing hundreds or thousands of client transactions and bank accounts. Many organizations rely on spreadsheets, which are risky, difficult to maintain, and lack real-time visibility. Month-end allocations and reconciliations further complicate client accounting and timely reporting. As a result, managers may […]
FQHCs: Navigating Financial and Operational Challenges Amid Federal Funding Uncertainty
AAFCPAs’ Matthew Hutt, Vassilis Kontoglis, and Ryan K. Wolff offered insights in an educational session titled Navigating Financial & Operational Challenges in FQHCs at CHI 2025! This session was ideal for health center CFOs, COOs, and other decision-makers looking to adapt to the current federal and state funding landscape. In this session, attendees explored how […]
Practical Applications for AI, Automation in Healthcare Finance
AI is reshaping healthcare finance and creating opportunities for providers to improve efficiency and financial performance. With government funding shortages, rising claim denials, and a competitive labor market, automation is becoming an essential tool. Third-party payors are already leveraging AI for claims processing, and providers may benefit from similar technologies. Consider just a few of […]
Streamlining Operations with a Modern ERP System
Incompass Human Services modernizes its financial and operational workflows, improving efficiency, compliance, and transparency. As the multi-service health and human services agency grew, despite its longstanding success, Incompass recognized the need to innovate to stay ahead of the evolving demands of the industry. Like many other large health and human services providers, the agency faced […]
Navigating Federal Funding Uncertainty: Financial Strategies for Nonprofits
Nonprofits across the country are facing an uncertain financial future as the federal funding freeze and shifting policies disrupt their budgets. Organizations that have long relied on stable government grants are now being forced to reassess their financial strategies, manage liquidity more carefully, and rethink how they maintain reserve funds. Evaluating Financial Reserves and Liquidity […]
340B Discounts at Risk: What It Means for FQHCs and Patient Care
Federally Qualified Health Centers (FQHCs), hospitals, and health systems relying on 340B discounts are facing growing uncertainty. Courts, policymakers, and pharmaceutical manufacturers continue to push for changes that could reshape how the program operates. Recent developments have highlighted potential new restrictions and increased oversight along with the financial strain for participating providers. FQHCs and hospitals […]
Upcoming Increase in Single Audit or Program-Specific Audit Thresholds
For audits of fiscal years beginning on or after October 1, 2024, the Office of Management and Budget (OMB) will raise the threshold for requiring a single audit or program-specific audit from $750,000 to $1,000,000. Non-Federal entities receiving less than $1,000,000 in federal funds annually will no longer be required to undergo a single audit, […]
Managing Cash Flow and Expenses in Life Sciences
In this article: Managing cash flow presents ongoing challenges for those in the life sciences, particularly those navigating pre-clinical research and early clinical stages. With significant resources devoted to research and development (R&D), precise cash tracking across R&D and general and administrative (G&A) categories is essential for sustaining growth and demonstrating financial responsibility. Distinguishing between […]
Tax Strategies Shaping Life Science Innovation
Life science companies, particularly those in the start-up or growth phase, are challenged with balancing their core mission, e.g., advancing scientific discovery, with the complex financial and tax issues that arise in the process. While pursuing breakthroughs in areas like cancer treatments or novel drugs, companies need to also ensure they retain enough capital to […]